AR018705A1 - Procedimientos e intermedios para preparar compuestos anticancerosos. - Google Patents

Procedimientos e intermedios para preparar compuestos anticancerosos.

Info

Publication number
AR018705A1
AR018705A1 ARP000101413A ARP000101413A AR018705A1 AR 018705 A1 AR018705 A1 AR 018705A1 AR P000101413 A ARP000101413 A AR P000101413A AR P000101413 A ARP000101413 A AR P000101413A AR 018705 A1 AR018705 A1 AR 018705A1
Authority
AR
Argentina
Prior art keywords
intermediates
procedures
target compounds
prepare anti
compounds
Prior art date
Application number
ARP000101413A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc, Pfizer Prod Inc filed Critical Osi Pharm Inc
Publication of AR018705A1 publication Critical patent/AR018705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a procedimientos e intermedios para preparar compuestos de formula (I) y sales y solvatos farmacéuticamente aceptables delos mismos, así como compuestos estructuralmente relacionados, formula en la que R1, R2 y R15so n como se han definido en la Memoria. Los compuestos antesmencionados son utiles en el tratamiento hiperproliferativos, como cánceres, en mamíferos.
ARP000101413A 1999-03-31 2000-03-29 Procedimientos e intermedios para preparar compuestos anticancerosos. AR018705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
AR018705A1 true AR018705A1 (es) 2001-11-28

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101413A AR018705A1 (es) 1999-03-31 2000-03-29 Procedimientos e intermedios para preparar compuestos anticancerosos.

Country Status (50)

Country Link
US (1) US6476040B1 (es)
EP (1) EP1044969B1 (es)
JP (2) JP3420549B2 (es)
KR (2) KR100430210B1 (es)
CN (2) CN100351242C (es)
AP (2) AP1655A (es)
AR (1) AR018705A1 (es)
AT (1) ATE348098T1 (es)
AU (2) AU781402B2 (es)
BG (1) BG65194B1 (es)
BR (1) BRPI0001486B8 (es)
CA (2) CA2302965C (es)
CO (1) CO5160273A1 (es)
CR (1) CR6165A (es)
CZ (1) CZ299426B6 (es)
DE (1) DE60032275T2 (es)
DK (1) DK1044969T3 (es)
DZ (1) DZ3030A1 (es)
EA (3) EA005561B1 (es)
EE (1) EE04589B1 (es)
EG (1) EG22506A (es)
ES (1) ES2278578T3 (es)
GE (1) GEP20022653B (es)
GT (1) GT200000037A (es)
HK (1) HK1029790A1 (es)
HR (1) HRP20000182B1 (es)
HU (1) HU227698B1 (es)
ID (1) ID25427A (es)
IL (2) IL168036A (es)
IS (1) IS2468B (es)
MA (1) MA25087A1 (es)
MY (1) MY136270A (es)
NO (2) NO321952B1 (es)
NZ (2) NZ512818A (es)
OA (1) OA11335A (es)
PA (1) PA8491901A1 (es)
PE (1) PE20001599A1 (es)
PL (1) PL339330A1 (es)
PT (1) PT1044969E (es)
RS (1) RS49836B (es)
SG (2) SG121687A1 (es)
SK (1) SK287339B6 (es)
SV (1) SV2002000047A (es)
TN (1) TNSN00064A1 (es)
TR (1) TR200000837A2 (es)
TW (1) TW553939B (es)
UA (2) UA70928C2 (es)
UY (1) UY26086A1 (es)
YU (1) YU13200A (es)
ZA (1) ZA200001586B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
NZ525324A (en) 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
JP4703183B2 (ja) 2002-07-15 2011-06-15 シンフォニー エボルーション， インク． 受容体型キナーゼモジュレーターおよびその使用方法
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
KR101218213B1 (ko) 2003-07-03 2013-01-04 시토비아 인크. 카스파제의 활성인자 및 세포자멸사의 유도인자로서의4-아릴아미노-퀴나졸린
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004272348B2 (en) 2003-09-16 2008-09-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
WO2006030826A1 (ja) 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
AU2006217692A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
WO2007136103A1 (ja) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
US20090203693A1 (en) * 2006-06-29 2009-08-13 Eisai R & D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
CA2675736A1 (en) 2007-01-19 2008-07-24 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
ES2573931T3 (es) 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090131665A1 (en) * 2007-08-23 2009-05-21 Ales Gavenda Process for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCI
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
WO2009121042A1 (en) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Quinazoline derivatives and methods of treatment
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
PL2387563T5 (pl) 2009-01-16 2023-03-13 Exelixis, Inc. Sól jabłczanowa N-(4-{[6,7-bis(metyloksy)chinolin-4-ylo]oksy}fenylo-N′-(4-fluorofenylo)cykloproano-1,1-dikarboksyamidu oraz jej krystaliczne postaci do leczenia raka
EP2411373B1 (en) 2009-03-26 2015-10-21 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2499118A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
JP5948597B2 (ja) 2010-07-23 2016-07-06 ジェネリクス・［ユーケー］・リミテッド 純粋なエルロチニブ
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
MX9707453A (es) * 1995-03-30 1997-12-31 Pfizer Derivados de quinazolina.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
IL125686A (en) 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
CA2244897C (en) 1996-03-05 2006-04-11 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
MXPA00010610A (es) 1998-04-29 2002-07-02 Osi Pharm Inc Mesilato de n-(e-etinilfenilamino)-6,7-bis (2-metoxietoxi)-4-quinazolinamina, anhidro y monohidratado.

Also Published As

Publication number Publication date
DE60032275D1 (de) 2007-01-25
GT200000037A (es) 2001-09-21
EG22506A (en) 2003-03-31
SK287339B6 (sk) 2010-07-07
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
EE04589B1 (et) 2006-02-15
EA200000274A2 (ru) 2000-10-30
NO20054715L (no) 2000-10-02
BG104278A (en) 2001-08-31
DK1044969T3 (da) 2007-04-23
KR100430210B1 (ko) 2004-05-03
CR6165A (es) 2008-10-10
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
CN1276370A (zh) 2000-12-13
HUP0001353A3 (en) 2002-01-28
CN1699350A (zh) 2005-11-23
OA11335A (en) 2003-12-10
SK4442000A3 (en) 2000-10-09
KR20010014658A (ko) 2001-02-26
GEP20022653B (en) 2002-03-25
JP4074509B2 (ja) 2008-04-09
UA80955C2 (en) 2007-11-26
SG121687A1 (en) 2006-05-26
EP1044969A3 (en) 2000-11-29
AU2005201494A1 (en) 2005-05-05
PA8491901A1 (es) 2001-12-14
DE60032275T2 (de) 2007-07-12
MA25087A1 (fr) 2000-10-01
JP2003176274A (ja) 2003-06-24
CO5160273A1 (es) 2002-05-30
SG115536A1 (en) 2005-10-28
DZ3030A1 (fr) 2004-03-27
YU13200A (sh) 2002-10-18
EA200000274A3 (ru) 2003-02-27
IS2468B (is) 2008-12-15
EA200201244A1 (ru) 2003-04-24
PE20001599A1 (es) 2001-01-18
CZ299426B6 (cs) 2008-07-23
CA2427221C (en) 2008-09-16
UA70928C2 (uk) 2004-11-15
BR0001486A (pt) 2001-05-02
AU2005201494B2 (en) 2008-02-07
CA2302965A1 (en) 2000-09-30
PT1044969E (pt) 2007-05-31
HU227698B1 (en) 2011-12-28
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
TW553939B (en) 2003-09-21
BRPI0001486B8 (pt) 2021-05-25
ATE348098T1 (de) 2007-01-15
UY26086A1 (es) 2000-10-31
SV2002000047A (es) 2002-01-23
CN1215061C (zh) 2005-08-17
EA005892B1 (ru) 2005-06-30
NO321952B1 (no) 2006-07-24
EA200201245A1 (ru) 2003-04-24
CN100351242C (zh) 2007-11-28
NZ503683A (en) 2001-09-28
HK1029790A1 (en) 2001-04-12
HUP0001353A2 (hu) 2001-05-28
AP1655A (en) 2006-09-01
CA2427221A1 (en) 2000-09-30
AP1265A (en) 2004-03-26
EA005561B1 (ru) 2005-04-28
EP1044969A2 (en) 2000-10-18
EP1044969B1 (en) 2006-12-13
AU781402B2 (en) 2005-05-19
CZ20001155A3 (cs) 2001-03-14
PL339330A1 (en) 2000-10-09
JP3420549B2 (ja) 2003-06-23
IL135245A0 (en) 2001-05-20
JP2000290262A (ja) 2000-10-17
EA004654B1 (ru) 2004-06-24
KR100430209B1 (ko) 2004-05-03
CA2302965C (en) 2004-02-17
US6476040B1 (en) 2002-11-05
ES2278578T3 (es) 2007-08-16
HU0001353D0 (en) 2000-06-28
ID25427A (id) 2000-10-05
RS49836B (sr) 2008-08-07
IS5411A (is) 2000-10-02
EE200000255A (et) 2000-12-15
ZA200001586B (en) 2001-10-01
NO20001648D0 (no) 2000-03-30
TR200000837A2 (tr) 2000-11-21
NZ512818A (en) 2003-01-31
BG65194B1 (bg) 2007-06-29
HRP20000182A2 (en) 2001-04-30
BRPI0001486B1 (pt) 2019-01-29
MY136270A (en) 2008-09-30
KR20020084903A (ko) 2002-11-13
NO20001648L (no) 2000-10-02

Similar Documents

Publication Publication Date Title
AR018705A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos.
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
UY26872A1 (es) Derivados de la 4- fenil piridina
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8544901A1 (es) Derivados de oxazol
ECSP066643A (es) PIRIDO [2,3-d] PIRIMIDINA-2,4-DIAMINAS COMO INHIBIDORES DE PDE 2
PA8593001A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PA8480101A1 (es) Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
UY28691A1 (es) Derivados de difenilazetidona
UY28572A1 (es) Compuestos novedosos
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
UY28695A1 (es) Derivados de difenilazetidona
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
PA8589801A1 (es) Aminoalcoxiindoles
UY27980A1 (es) Indoles 2,7-sustituidos
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR028947A1 (es) Compuestos novedosos

Legal Events

Date Code Title Description
FG Grant, registration